Immunovant, Inc. (IMVT) Dividend History

Company News

• IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

  Immunovant's (IMVT) investigational candidate, batoclimab, showed positive data in a mid-stage study for Graves' Disease, leading to a rise in the company's stock. The data demonstrated significant reductions in Immunoglobin G levels and high response rates in the patient population.

  Benzinga

  Featured Companies: FULC ILMN KRYS
• Immunovant Provides Update on Graves’ Disease Development Program

  Immunovant's batoclimab achieved a 76% response rate in Graves' Disease patients uncontrolled on antithyroid drugs (ATDs) at week 12. The company also reported a strong correlation between IgG lowering and clinical outcomes, indicating a potential best-in-class and first-in-class opportunity for IMVT-1402 in Graves' Disease.

  GlobeNewswire Inc.
• Thyroid Eye Disease Market to Accelerate Substantially by 2034, Assesses DelveInsight | Key Companies Developing ... - GlobeNewswire

  The thyroid eye disease market is expected to show good positive growth by 2034, driven by new product launches, a robust pipeline of emerging therapies, and an increase in the geriatric population.

  GlobeNewswire Inc.

  Featured Companies: AMGN TRML VRDN
• Immunovant (IMVT) Down 1.6% Since Last Earnings Report: Can It Rebound?

  Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  Zacks Investment Research
• Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus

  Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.

  Zacks Investment Research

  Featured Companies: ALXO BHVN ENTX